Experts Discuss CELMoDs in Myeloma
In this podcast, experts discuss CELMoD therapy for multiple myeloma, including mechanism of action, available clinical data and ongoing trials, and future implications.
Decera Clinical Education Oncology Podcast · Jesus Berdeja MD, Amrita Krishnan MD FACP, Sagar Lonial MD FACP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including:
- Mechanistic differences between CELMoDs and IMiDs
- Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
- The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma
Presenters:
Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia
Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.
Link to full program:
https://bit.ly/3IwbslQ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.